Monopar Therapeutics Inc (MNPR)

Etorro trading 970x250
Monopar Therapeutics Inc (MNPR) Logo

About Monopar Therapeutics Inc

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois. Address: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091

Monopar Therapeutics Inc News and around…

Latest news about Monopar Therapeutics Inc (MNPR) common stock and company :

12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Oct, 2021 FinancialContent

Gainers Tenet Healthcare (NYSE:THC) stock rose 7.06% to $70.3 during Wednesday's after-market session. Today's trading volume for ...

Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth
22 Sep, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
16 Sep, 2021 FinancialContent
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
13 Sep, 2021 FinancialContent
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
13 Sep, 2021 Yahoo! Finance

Trial launch in Europe coincides with the Company’s upcoming presentation at the European Society for Medical Oncology Congress WILMETTE, Ill., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has received authorization to proceed with the Phase 2b/3 VOICE clinical trial in France. The

Monopar Therapeutics to Present at Upcoming Investor Conferences in September
09 Sep, 2021 FinancialContent
54 Biggest Movers From Yesterday
09 Sep, 2021 FinancialContent

Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) shares jumped 111.8% to settle at $27.17 on Wednesday after jumping 50% on ...

Implied IWC Analyst Target Price: $202
02 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $202.17 per unit.

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
12 Aug, 2021 FinancialContent
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
05 Aug, 2021 FinancialContent
Monopar Stock Gains On Launch Of Early Stage Soft Tissue Cancer Trial With Camsirubicin
03 Aug, 2021 FinancialContent

TheFDA has signed offMonopar Therapeutics Inc's(NASDAQ: MNPR) IND to commence an open-label Phase 1b ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
03 Aug, 2021 FinancialContent

Gainers Outlook Therapeutics (NASDAQ:OTLK) shares increased by 38.49% to $3.13 during Tuesday's pre-market session. ...

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
03 Aug, 2021 FinancialContent
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
12 Jul, 2021 FinancialContent
Look Under The Hood: IWC Has 21% Upside
28 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $187.98 per unit.

12 Health Care Stocks Moving In Friday's Pre-Market Session
25 Jun, 2021 FinancialContent

Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) shares increased by 39.08% to $3.95 during Friday's pre-market ...

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
24 Jun, 2021 FinancialContent
Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings
03 Jun, 2021 FinancialContent

Monopar Therapeutics Inc(NASDAQ: MNPR)collaborateswith the Cancer Science Institute of Singapore to evaluate the ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
03 Jun, 2021 FinancialContent

Gainers Sundial Growers (NASDAQ:SNDL) shares rose 9.73% to $1.24 during Thursday's pre-market session. The ...

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
03 Jun, 2021 FinancialContent

Development of novel Camsirubicin analog expands Monopar’s therapeutic pipeline

Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
01 Jun, 2021 FinancialContent
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic
26 May, 2021 FinancialContent
IWC's Underlying Holdings Could Mean 26% Gain Potential
25 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $182.86 per unit.

12 Health Care Stocks Moving In Monday's Pre-Market Session
24 May, 2021 FinancialContent

Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market ...

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
24 May, 2021 FinancialContent

Potential to significantly improve the yield of Actinium-based radiopharmaceuticals

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
13 May, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
22 Apr, 2021 FinancialContent

Gainers Ocugen (NASDAQ:OCGN) stock moved upwards by 7.1% to $9.95 during Thursday's after-market session. At the close, ...

We Did The Math IWC Can Go To $176
20 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $176.45 per unit.

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
13 Apr, 2021 FinancialContent

NorthStar Medical Radioisotopes announced a corporate update describing progress in its key programs during the past year and upcoming milestones.

71 Biggest Movers From Yesterday
01 Apr, 2021 FinancialContent

Gainers Discovery, Inc. (NASDAQ: DISCB) shares gained 82.8% to close at $128.00 after climbing around 29% on Tuesday. Wah Fu ...

Monopar Therapeutics Inc (MNPR) is a NASDAQ Common Stock listed in , ,

970x250